CHIP mutations generally involve genes implicated in hematologic cancer, but can affect CRC associated genes, such as TP53 and KRAS, contributing to false-positive results [65,66]. This evidence concerns the gene TP53 and hematopoietic and lymphoid cell neoplasm.